Nektar Therapeutics (NKTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nektar Therapeutics (NKTR) has a cash flow conversion efficiency ratio of -0.573x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.76 Million) by net assets ($85.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nektar Therapeutics - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how Nektar Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Nektar Therapeutics for a breakdown of total debt and financial obligations.
Nektar Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nektar Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eyebright Medical Technology Beijing Co Ltd
SHG:688050
|
0.026x |
|
Longkou Union Chemical Co. Ltd. A
SHE:301209
|
0.008x |
|
Three's Company Media Group Co Ltd
SHG:605168
|
-0.021x |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
-0.086x |
|
NCAB Group
ST:NCAB
|
0.199x |
|
TGS ASA SP.ADR/1
F:TGC0
|
N/A |
|
Jiangsu Zongyi Co Ltd
SHG:600770
|
0.009x |
|
La-Z-Boy Incorporated
NYSE:LZB
|
0.048x |
Annual Cash Flow Conversion Efficiency for Nektar Therapeutics (1994–2024)
The table below shows the annual cash flow conversion efficiency of Nektar Therapeutics from 1994 to 2024. For the full company profile with market capitalisation and key ratios, see NKTR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.74 Million | $-175.71 Million | -2.893x | -96.74% |
| 2023-12-31 | $130.99 Million | $-192.61 Million | -1.470x | -77.34% |
| 2022-12-31 | $366.64 Million | $-304.01 Million | -0.829x | -36.54% |
| 2021-12-31 | $679.51 Million | $-412.66 Million | -0.607x | -108.83% |
| 2020-12-31 | $1.08 Billion | $-313.29 Million | -0.291x | -24.35% |
| 2019-12-31 | $1.41 Billion | $-328.68 Million | -0.234x | -155.93% |
| 2018-12-31 | $1.72 Billion | $718.21 Million | 0.418x | +145.67% |
| 2017-12-31 | $87.83 Million | $-80.41 Million | -0.916x | +31.05% |
| 2016-12-31 | $88.12 Million | $-117.02 Million | -1.328x | +88.32% |
| 2015-12-31 | $6.43 Million | $-73.08 Million | -11.368x | -190.84% |
| 2014-12-31 | $36.33 Million | $-142.01 Million | -3.909x | -1012.07% |
| 2013-12-31 | $-89.90 Million | $-38.53 Million | 0.429x | +115.53% |
| 2012-12-31 | $47.02 Million | $-129.76 Million | -2.760x | -379.95% |
| 2011-12-31 | $197.81 Million | $-113.74 Million | -0.575x | +6.69% |
| 2010-12-31 | $90.66 Million | $-55.87 Million | -0.616x | -258.75% |
| 2009-12-31 | $102.37 Million | $39.74 Million | 0.388x | +150.64% |
| 2008-12-31 | $190.15 Million | $-145.78 Million | -0.767x | -212.37% |
| 2007-12-31 | $214.44 Million | $146.30 Million | 0.682x | +267.08% |
| 2006-12-31 | $227.06 Million | $-92.72 Million | -0.408x | -71.09% |
| 2005-12-31 | $326.81 Million | $-78.00 Million | -0.239x | -42.74% |
| 2004-12-31 | $467.34 Million | $-78.14 Million | -0.167x | +63.97% |
| 2003-12-31 | $164.19 Million | $-76.20 Million | -0.464x | -27.99% |
| 2002-12-31 | $206.77 Million | $-74.97 Million | -0.363x | -93.04% |
| 2001-12-31 | $270.31 Million | $-50.77 Million | -0.188x | -46.04% |
| 2000-12-31 | $277.88 Million | $-35.74 Million | -0.129x | +27.34% |
| 1999-12-31 | $86.63 Million | $-15.33 Million | -0.177x | -6.70% |
| 1998-12-31 | $115.88 Million | $-19.22 Million | -0.166x | -423.49% |
| 1997-12-31 | $97.09 Million | $4.98 Million | 0.051x | +131.03% |
| 1996-12-31 | $35.10 Million | $-5.80 Million | -0.165x | +37.02% |
| 1995-12-31 | $20.20 Million | $-5.30 Million | -0.262x | -1.01% |
| 1994-12-31 | $15.40 Million | $-4.00 Million | -0.260x | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; P… Read more